| Kidney and lung ACE2 expression after an ACE inhibitor or an Ang II receptor blocker: implications for COVID-19 J Wysocki, E Lores, M Ye, MJ Soler, D Batlle Journal of the American Society of Nephrology 31 (9), 1941-1943, 2020 | 112 | 2020 |
| Cuffless blood pressure monitoring: promises and challenges JA Pandit, E Lores, D Batlle Clinical Journal of the American Society of Nephrology 15 (10), 1531-1538, 2020 | 72 | 2020 |
| ACE2, the kidney and the emergence of COVID-19 two decades after ACE2 discovery E Lores, J Wysocki, D Batlle Clinical Science 134 (21), 2791-2805, 2020 | 17 | 2020 |
| Urinary angiotensinogen antedates the development of stage 3 CKD in patients with type 1 diabetes mellitus S Ba Aqeel, M Ye, J Wysocki, A Sanchez, A Khattab, E Lores, ... Physiological Reports 7 (19), e14242, 2019 | 8 | 2019 |
| Kidney and Lung ACE2 Expression After an ACE Inhibitor or an Angiotensin II Receptor Blocker: Implications for COVID-19: PO0834 E Lores, J Wysocki, M Ye, MJ Soler, D Batlle Journal of the American Society of Nephrology 31 (10S), 296-297, 2020 | | 2020 |
| Supplement to Research Letter J Wysocki, E Lores, M Ye, MJ Soler, D Batlle | | |
